Inhibition of bacterial type II topoisomerases
Biochemical assay · Purified E. coli KL-16 DNA gyrase and S. aureus FDA 209-P topoisomerase IV. [1]
Electrophoretic enzyme assays compared sitafloxacin with three stereoisomers and levofloxacin, ofloxacin and ciprofloxacin. Sitafloxacin had the lowest IC50 against each bacterial enzyme in this panel.
| Endpoint | Reported result | Reference |
|---|---|---|
| Inhibition of DNA gyrase supercoiling | IC50 0.13 ± 0.01 μg/ml (IC50 ± SD) | [1] |
| Inhibition of topoisomerase IV decatenation | IC50 0.39 ± 0.15 μg/ml (IC50 ± SD) | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- DNA gyrase reaction: 1 h; topoisomerase IV reaction duration not stated in the retrieved paragraph.
- Method
- Electrophoretic enzyme-activity assays; DNA gyrase reaction at 37°C.
- Reported limits
- IC50 values are assay endpoints, not treatment concentrations. Replicate number and drug solvent are not stated in the selected enzyme-method text.
Methods and source locations
Compound reported in the paper: Sitafloxacin; Compound label in the paper: DU-6859a
Evidence concerns the reported sesquihydrate. Values remain in reported mass units; no conversion to the catalog anhydrous formula or Adooq lot validation.
Table 2; enzyme-source and electrophoretic enzyme-assay paragraphs; Introduction and Figure 1
Inhibition of DNA gyrase supercoiling: Gel-based quantification of supercoiled plasmid DNA. — Table 2, Sitafloxacin row and footnote; electrophoretic enzyme-assay paragraph
Inhibition of topoisomerase IV decatenation: Concentration reducing decatenation by 50% relative to drug-free controls. — Table 2, Sitafloxacin row and footnote; electrophoretic enzyme-assay paragraph